Cyclin-dependent kinase 4 may be expressed as multiple proteins and have functions that are independent of binding to CCND and RB and occur at the S and G2/M phases of the cell cycle

Cell Cycle

Volumn 12, Issue 22, 2013, Pages 3512-3525

  Sun, Yuan ^a   Lou, Xiaomin ^b   Yang, Min ^a   Yuan, Chengfu ^a   Ma, Ling ^a   Xie, Bing Kun ^a   Wu, Jian Min ^a   Yang, Wei ^a   Shen, Steven X J ^c   Xu, Ningzhi ^d   Liao, D Joshua ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Chinese Academy of Sciences and China National Center for Bioinformation   (China)

^c DURHAM VA MEDICAL CENTER   (United States)

^d CANCER HOSPITAL   (China)

Author keywords

Alternative splicing; CCND1; CDK4; Cell cycle; RB1

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE 4; MESSENGER RNA;

ARTICLE; CELL CYCLE S PHASE; CELL DEATH; CELL GROWTH; CHROMOSOME 1; EXON; G2 PHASE CELL CYCLE CHECKPOINT; GENE DOSAGE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MOLECULAR CLONING; MOUSE; NONHUMAN; ONCOGENE C MYC; PANCREAS CANCER; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PSEUDOGENE; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; START CODON; STOP CODON; TANDEM MASS SPECTROMETRY;

ALTERNATIVE SPLICING; CCND1; CDK4; CELL CYCLE; RB1;

ANIMALS; APOPTOSIS; CELL LINE; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; ISOENZYMES; M PHASE CELL CYCLE CHECKPOINTS; MICE; MUTATION; RETINOBLASTOMA PROTEIN; S PHASE CELL CYCLE CHECKPOINTS;

EID: 84890348620     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26510     Document Type: Article

References (70)

1. Bates S, Parry D, Bonetta L, Vousden K, Dickson C, Peters G. Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene 1994; 9:1633-40; PMID:8183557 (Pubitemid 24163389)
2. Burgess A, Wigan M, Giles N, Depinto W, Gillespie P, Stevens F, Gabrielli B. Inhibition of S/G2 phase CDK4 reduces mitotic fidelity. J Biol Chem 2006; 281:9987-95; PMID:16476733; http://dx.doi.org/10.1074/jbc.M512714200 (Pubitemid 43864531)
3. Gabrielli BG, Sarcevic B, Sinnamon J, Walker G, Castellano M, Wang XQ, Ellem KA. A cyclin D-Cdk4 activity required for G2 phase cell cycle progression is inhibited in ultraviolet radiation-induced G2 phase delay. J Biol Chem 1999; 274:13961-9; PMID:10318807; http://dx.doi.org/10.1074/jbc.274.20.13961
4. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY. D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 1994; 14:2066-76; PMID:8114738 (Pubitemid 24074604)
5. Liao DJ, Thakur A, Wu J, Biliran H, Sarkar FH. Perspectives on c-Myc, Cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. Crit Rev Oncog 2007; 13:93-158; PMID:18197790; http://dx.doi.org/10.1615/CritRevOncog.v13.i2.10 (Pubitemid 350274298)
6. Wang C, Lisanti MP, Liao DJ. Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle 2011; 10:57-67; PMID:21200143; http://dx.doi.org/10.4161/cc.10.1.14449
7. De Vivo M, Bottegoni G, Berteotti A, Recanatini M, Gervasio FL, Cavalli A. Cyclin-dependent kinases: bridging their structure and function through computations. Future Med Chem 2011; 3:1551-9; PMID:21882947; http://dx.doi.org/10.4155/fmc.11.113
8. Day PJ, Cleasby A, Tickle IJ, O?Reilly M, Coyle JE, Holding FP, McMenamin RL, Yon J, Chopra R, Lengauer C, et al. Crystal structure of human CDK4 in complex with a D-type cyclin. Proc Natl Acad Sci U S A 2009; 106:4166-70; PMID:19237565; http://dx.doi.org/10.1073/pnas.0809645106
9. Takaki T, Echalier A, Brown NR, Hunt T, Endicott JA, Noble ME. The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc Natl Acad Sci U S A 2009; 106:4171-6; PMID:19237555; http://dx.doi.org/10.1073/ pnas.0809674106
10. Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde KH, Beach D. A p16INK4ainsensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269:1281-4; PMID:7652577; http://dx.doi.org/10. 1126/science.7652577
11. Coleman KG, Wautlet BS, Morrissey D, Mulheron J, Sedman SA, Brinkley P, Price S, Webster KR. Identification of CDK4 sequences involved in cyclin D1 and p16 binding. J Biol Chem 1997; 272:18869-74; PMID:9228064; http://dx.doi.org/10. 1074/jbc.272.30.18869 (Pubitemid 27318237)
12. Geng Y, Lee YM, Welcker M, Swanger J, Zagozdzon A, Winer JD, Roberts JM, Kaldis P, Clurman BE, Sicinski P. Kinase-independent function of cyclin E. Mol Cell 2007; 25:127-39; PMID:17218276; http://dx.doi.org/10.1016/j.molcel.2006.11. 029 (Pubitemid 46049064)
13. Lobanov AV, Turanov AA, Hatfield DL, Gladyshev VN. Dual functions of codons in the genetic code. Crit Rev Biochem Mol Biol 2010; 45:257-65; PMID:20446809; http://dx.doi.org/10.3109/10409231003786094
14. Jungreis I, Lin MF, Spokony R, Chan CS, Negre N, Victorsen A, White KP, Kellis M. Evidence of abundant stop codon readthrough in Drosophila and other metazoa. Genome Res 2011; 21:2096-113; PMID:21994247; http://dx.doi.org/10.1101/ gr.119974.110
15. Sánchez-Sánchez F, Ramírez-Castillejo C, Weekes DB, Beneyto M, Prieto F, Nájera C, Mittnacht S. Attenuation of disease phenotype through alternative translation initiation in low-penetrance retinoblastoma. Hum Mutat 2007; 28:159-67; PMID:16988938; http://dx.doi.org/10. 1002/humu.20394 (Pubitemid 46233313)
16. Liao DJ, Dickson RB. c-Myc in breast cancer. Endocr Relat Cancer 2000; 7:143-64; PMID:11021963; http://dx.doi.org/10.1677/erc.0.0070143
17. Sun Y, Li Y, Luo D, Liao DJ. Pseudogenes as weaknesses of ACTB (Actb) and GAPDH (Gapdh) used as reference genes in reverse transcription and polymerase chain reactions. PLoS One 2012; 7:e41659; PMID:22927912; http://dx.doi.org/10. 1371/journal. pone.0041659
18. Yang M, Sun Y, Ma L, Wang C, Wu JM, Bi A, Liao DJ. Complex alternative splicing of the smarca2 gene suggests the importance of smarca2-B variants. J Cancer 2011; 2:386-400; PMID:21811517; http://dx.doi.org/10.7150/jca.2.386
19. Yang M, Wu J, Wu SH, Bi AD, Liao DJ. Splicing of mouse p53 pre-mRNA does not always follow the "first come, first served" principle and may be influenced by cisplatin treatment and serum starvation. Mol Biol Rep 2012; 39:9247-56; PMID:22740133; http://dx.doi.org/10.1007/s11033-012-1798-2
20. Sun Y, Cao S, Yang M, Wu S, Wang Z, Lin X, Song X, Liao DJ. Basic anatomy and tumor biology of the RPS6KA6 gene that encodes the p90 ribosomal S6 kinase-4. Oncogene 2013; 32:1794-810; PMID:22614021; http://dx.doi.org/10.1038/ onc.2012.200
21. Liao DZ, Hou X, Bai S, Li SA, Li JJ. Unusual deregulation of cell cycle components in early and frank estrogen-induced renal neoplasias in the Syrian hamster. Carcinogenesis 2000; 21:2167-73; PMID:11133805; http://dx.doi.org/10. 1093/carcin/21.12.2167 (Pubitemid 32049222)
22. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, Barbacid M. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 1999; 22:44-52; PMID:10319860; http://dx.doi.org/10.1038/8751
23. Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, Kiyokawa H. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol 1999; 19:7011-9; PMID:10490638 (Pubitemid 29441883)
24. Planas-Silva MD, Weinberg RA. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 1997; 17:4059-69; PMID:9199341 (Pubitemid 27281882)
25. Gu Y, Rosenblatt J, Morgan DO. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J 1992; 11:3995-4005; PMID:1396589
26. Bockstaele L, Kooken H, Libert F, Paternot S, Dumont JE, de Launoit Y, Roger PP, Coulonval K. Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK "inhibitors". Mol Cell Biol 2006; 26:5070-85; PMID:16782892; http://dx.doi.org/10.1128/MCB.02006-05 (Pubitemid 43955820)
27. Nudelman I, Glikin D, Smolkin B, Hainrichson M, Belakhov V, Baasov T. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem 2010; 18:3735-46; PMID:20409719; http://dx.doi.org/ 10.1016/j.bmc.2010.03.060
28. Heier CR, DiDonato CJ. Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. Hum Mol Genet 2009; 18:1310-22; PMID:19150990; http://dx.doi.org/10.1093/hmg/ddp030
29. Floquet C, Deforges J, Rousset JP, Bidou L. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res 2011; 39:3350-62; PMID:21149266; http://dx.doi.org/10.1093/nar/gkq1277
30. He G, Kuang J, Khokhar AR, Siddik ZH. The impact of S-and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a noncross-resistant platinum(IV) analog. Gynecol Oncol 2011; 122:402-9; PMID:21592546; http://dx.doi.org/10.1016/j.ygyno.2011.04.034
31. Lukas J, Bartkova J, Rohde M, Strauss M, Bartek J. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol 1995; 15:2600-11; PMID:7739541
32. El-Kady A, Sun Y, Li YX, Liao DJ. Cyclin D1 inhibits whereas c-Myc enhances the cytotoxicity of cisplatin in mouse pancreatic cancer cells via regulation of several members of the NF-?B and Bcl-2 families. J Carcinog 2011; 10:24; PMID:22190866; http://dx.doi.org/10.4103/1477-3163.90437
33. Sun Y, Li YX, Wu HJ, Wu SH, Wang YA, Luo DZ, Liao DJ. Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells. J Cancer 2011; 2:36-51; PMID:21234300; http://dx.doi.org/10.7150/jca.2.36
34. Sun Y, Luo D, Liao DJ. CyclinD1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-MB231 cells. J Carcinog 2012; 11:12; PMID:23233819; http://dx.doi.org/10.4103/1477-3163.100401
35. Vila-Perelló M, Muir TW. Biological applications of protein splicing. Cell 2010; 143:191-200; PMID:20946979; http://dx.doi.org/10.1016/j. cell.2010.09.031
36. Volkmann G, Mootz HD. Recent progress in intein research: from mechanism to directed evolution and applications. Cell Mol Life Sci 2013; 70:1185-206; PMID:22926412; http://dx.doi.org/10.1007/s00018-012-1120-4
37. Majmudar JD, Martin BR. Strategies for profiling native S-nitrosylation. Biopolymers 2013; PMID:23828013; http://dx.doi.org/10.1002/bip.22342
38. Gillery P, Jaisson S. Usefulness of non-enzymatic post-translational modification derived products (PTMDPs) as biomarkers of chronic diseases. J Proteomics 2013; PMID:23459210; http://dx.doi.org/10.1016/j.jprot.2013.02.015
39. Aggarwal P, Vaites LP, Kim JK, Mellert H, Gurung B, Nakagawa H, Herlyn M, Hua X, Rustgi AK, McMahon SB, et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell 2010; 18:329-40; PMID:20951943; http://dx.doi.org/10.1016/j.ccr.2010.08.012
40. Iacono M, Mignone F, Pesole G. uAUG and uORFs in human and rodent 5'untranslated mRNAs. Gene 2005; 349:97-105; PMID:15777708; http://dx.doi.org/ 10.1016/j.gene.2004.11.041
41. Ivanov IP, Atkins JF, Michael AJ. A profusion of upstream open reading frame mechanisms in polyamine-responsive translational regulation. Nucleic Acids Res 2010; 38:353-9; PMID:19920120; http://dx.doi.org/10.1093/nar/gkp1037
42. Ivanov IP, Firth AE, Michel AM, Atkins JF, Baranov PV. Identification of evolutionarily conserved non-AUG-initiated N-terminal extensions in human coding sequences. Nucleic Acids Res 2011; 39:4220-34; PMID:21266472; http://dx.doi.org/10.1093/nar/gkr007
43. Gerashchenko MV, Lobanov AV, Gladyshev VN. Genome-wide ribosome profiling reveals complex translational regulation in response to oxidative stress. Proc Natl Acad Sci U S A 2012; 109:17394-9; PMID:23045643; http://dx.doi.org/10.1073/ pnas.1120799109
44. Kochetov AV. Alternative translation start sites and hidden coding potential of eukaryotic mRNAs. Bioessays 2008; 30:683-91; PMID:18536038; http://dx.doi.org/10.1002/bies.20771 (Pubitemid 351898017)
45. Shatsky IN, Dmitriev SE, Terenin IM, Andreev DE. Cap-and IRES-independent scanning mechanism of translation initiation as an alternative to the concept of cellular IRESs. Mol Cells 2010; 30:285-93; PMID:21052925; http://dx.doi.org/10.1007/s10059-010-0149-1
46. Bollig-Fischer A, Thakur A, Sun Y, Wu J-S, Liao DJ. The predominant proteins that react to the MC-20 estrogen receptor alpha antibody differ in molecular weight between the mammary gland and uterus in the mouse and rat. Int J Biomed Sci 2012; 8:51-63; PMID:23675257
47. Paek KY, Park SM, Hong KY, Jang SK. Capdependent translation without base-by-base scanning of an messenger ribonucleic acid. Nucleic Acids Res 2012; 40:7541-51; PMID:22638585; http://dx.doi.org/10.1093/nar/gks471
48. Yuan C, Liu Y, Yang M, Liao DJ. New methods as alternative or corrective measures for the pitfalls and artifacts of reverse transcription and polymerase chain reactions (RT-PCR) in cloning chimeric or antisense-accompanied RNA. RNA Biol 2013; 10:958-68; PMID:23618925; http://dx.doi.org/10.4161/rna.24570
49. Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M, Nakamura M, Nishida H, Yap CC, Suzuki M, Kawai J, et al.; RIKEN Genome Exploration Research Group; Genome Science Group (Genome Network Project Core Group); FANTOM Consortium. Antisense transcription in the mammalian transcriptome. Science 2005; 309:1564-6; PMID:16141073; http://dx.doi.org/10.1126/science.1112009
50. Numata K, Kiyosawa H. Genome-wide impact of endogenous antisense transcripts in eukaryotes. Front Biosci (Landmark Ed) 2012; 17:300-15; PMID:22201745; http://dx.doi.org/10.2741/3928
51. Li K, Ramchandran R. Natural antisense transcript: a concomitant engagement with protein-coding transcript. Oncotarget 2010; 1:447-52; PMID:21311100
52. Skipper M, Dhand R, Campbell P. Presenting ENCODE. Nature 2012; 489:45; PMID:22955612; http://dx.doi.org/10.1038/489045a
53. Swami M. Small RNAs: Sorting the strands. Nat Rev Genet 2010; 11:6; PMID:20050274; http://dx.doi.org/10.1038/nrg2721
54. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012; 11:125-40; PMID:22262036
55. Czech B, Hannon GJ. Small RNA sorting: matchmaking for Argonautes. Nat Rev Genet 2011; 12:19-31; PMID:21116305; http://dx.doi.org/10.1038/nrg2916
56. Snow EC. Cyclin independent role for cdk4/6 during B cell lymphoma survival. Cell Cycle 2010; 9:2932; PMID:20703096; http://dx.doi.org/10.4161/cc. 9.15.12708
57. Gumina MR, Xu C, Chiles TC. Cyclin D3 is dispensable for human diffuse large B-cell lymphoma survival and growth: evidence for redundancy with cyclin E. Cell Cycle 2010; 9:820-8; PMID:20107311; http://dx.doi.org/10.4161/cc.9.4. 10783
58. Warenius HM, Kilburn JD, Essex JW, Maurer RI, Blaydes JP, Agarwala U, Seabra LA. Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4. Mol Cancer 2011; 10:72; PMID:21668989; http://dx.doi.org/10.1186/1476-4598-10-72
59. Gu W, Wang C, Li W, Hsu FN, Tian L, Zhou J, Yuan C, Xie XJ, Jiang T, Addya S, et al. Tumor-suppressive effects of CDK8 in endometrial cancer cells. Cell Cycle 2013; 12:987-99; PMID:23454913; http://dx.doi.org/10.4161/cc.24003
60. Yuan C, Xu N, Liao J. Switch of FANCL, a key FA-BRCA component, between tumor suppressor and promoter by alternative splicing. Cell Cycle 2012; 11:3356; PMID:22918243; http://dx.doi.org/10.4161/cc.21852
61. Goodwin EC, DiMaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci U S A 2000; 97:12513-8; PMID:11070078; http://dx.doi.org/10.1073/pnas.97.23.12513
62. Li J, Belogortseva N, Porter D, Park M. Chmp1A functions as a novel tumor suppressor gene in human embryonic kidney and ductal pancreatic tumor cells. Cell Cycle 2008; 7:2886-93; PMID:18787405; http://dx.doi.org/10.4161/cc.7.18. 6677
63. Numa F, Hirabayashi K, Tsunaga N, Kato H, O'Rourke K, Shao H, Stechmann-Lebakken C, Varani J, Rapraeger A, Dixit VM. Elevated levels of syndecan-1 expression confer potent serum-dependent growth in human 293T cells. Cancer Res 1995; 55:4676-80; PMID:7553648
64. Navarro F, Gutman D, Meire E, Cáceres M, Rigoutsos I, Bentwich Z, Lieberman J. miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53. Blood 2009; 114:2181-92; PMID:19584398; http://dx.doi.org/10.1182/blood-2009-02-205062
65. Biswas SC, Liu DX, Greene LA. Bim is a direct target of a neuronal E2F-dependent apoptotic pathway. J Neurosci 2005; 25:8349-58; PMID:16162916; http://dx.doi.org/10.1523/JNEUROSCI.1570-05.2005 (Pubitemid 41324721)
66. Sun Y, Sriramajayam K, Luo D, Liao DJ. A quick, costfree method of purification of DNA fragments from agarose gel. J Cancer 2012; 3:93-5; PMID:22359530; http://dx.doi.org/10.7150/jca.4163
67. Wang Y, Thakur A, Sun Y, Wu J, Biliran H, Bollig A, Liao DJ. Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice. Cancer Res 2007; 67:3698-707; PMID:17440082; http://dx.doi.org/10.1158/0008-5472.CAN-06-4000 (Pubitemid 46762155)
68. Meng B, Qian Z, Wei F, Wang W, Zhou C, Wang Z, Wang Q, Tong W, Wang Q, Ma Y, et al. Proteomic analysis on the temperature-dependent complexes in Thermoanaerobacter tengcongensis. Proteomics 2009; 9:3189-200; PMID:19526551; http://dx.doi.org/10.1002/pmic.200800650
69. Biliran H Jr., Wang Y, Banerjee S, Xu H, Heng H, Thakur A, Bollig A, Sarkar FH, Liao JD. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 2005; 11:6075-86; PMID:16115953; http://dx.doi.org/10.1158/1078-0432.CCR-04-2419 (Pubitemid 41170340)
70. Biliran H Jr., Banerjee S, Thakur A, Sarkar FH, Bollig A, Ahmed F, Wu J, Sun Y, Liao JD. c-Mycinduced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells. Clin Cancer Res 2007; 13:2811-21; PMID:17473215; http://dx.doi.org/10. 1158/1078-0432.CCR-06-1844 (Pubitemid 46788051)